Contrast Agents for Hepatocellular Carcinoma Imaging: Value and Progression
- PMID: 35720001
- PMCID: PMC9200965
- DOI: 10.3389/fonc.2022.921667
Contrast Agents for Hepatocellular Carcinoma Imaging: Value and Progression
Abstract
Hepatocellular carcinoma (HCC) has the third-highest incidence in cancers and has become one of the leading threats to cancer death. With the research on the etiological reasons for cirrhosis and HCC, early diagnosis has been placed great hope to form a favorable prognosis. Non-invasive medical imaging, including the associated contrast media (CM)-based enhancement scan, is taking charge of early diagnosis as mainstream. Meanwhile, it is notable that various CM with different advantages are playing an important role in the different imaging modalities, or even combined modalities. For both physicians and radiologists, it is necessary to know more about the proper imaging approach, along with the characteristic CM, for HCC diagnosis and treatment. Therefore, a summarized navigating map of CM commonly used in the clinic, along with ongoing work of agent research and potential seeded agents in the future, could be a needed practicable aid for HCC diagnosis and prognosis.
Keywords: CECT; MRI; contrast media (CM); hepatocellular carcinoma (HCC); ultrasound.
Copyright © 2022 Zhang, Numata, Du and Maeda.
Conflict of interest statement
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Figures




Similar articles
-
Application of Gd-EOB-DTPA-enhanced magnetic resonance imaging (MRI) in hepatocellular carcinoma.World J Surg Oncol. 2020 Aug 22;18(1):219. doi: 10.1186/s12957-020-01996-4. World J Surg Oncol. 2020. PMID: 32828123 Free PMC article. Review.
-
Comparison of Contrast Enhanced Ultrasound With Contrast Enhanced Computed Tomography for the Diagnosis of Hepatocellular Carcinoma.J Clin Exp Hepatol. 2017 Sep;7(3):222-229. doi: 10.1016/j.jceh.2017.03.003. Epub 2017 Mar 16. J Clin Exp Hepatol. 2017. PMID: 28970709 Free PMC article.
-
Usefulness of combination of imaging modalities in the diagnosis of hepatocellular carcinoma using Sonazoid®-enhanced ultrasound, gadolinium diethylene-triamine-pentaacetic acid-enhanced magnetic resonance imaging, and contrast-enhanced computed tomography.Oncology. 2011;81 Suppl 1:66-72. doi: 10.1159/000333264. Epub 2011 Dec 22. Oncology. 2011. PMID: 22212939
-
Non-enhanced magnetic resonance imaging as a surveillance tool for hepatocellular carcinoma: Comparison with ultrasound.J Hepatol. 2020 Apr;72(4):718-724. doi: 10.1016/j.jhep.2019.12.001. Epub 2019 Dec 10. J Hepatol. 2020. PMID: 31836549 Clinical Trial.
-
Management of hepatocellular carcinoma: The role of contrast-enhanced ultrasound.World J Radiol. 2014 Jan 28;6(1):7-14. doi: 10.4329/wjr.v6.i1.7. World J Radiol. 2014. PMID: 24578787 Free PMC article. Review.
Cited by
-
Recent Advances in Locoregional Therapy of Hepatocellular Carcinoma.Cancers (Basel). 2023 Jun 26;15(13):3347. doi: 10.3390/cancers15133347. Cancers (Basel). 2023. PMID: 37444457 Free PMC article. Review.
-
Effect of body mass index (BMI) on image contrast in the hepatobiliary phase of Gd-EOB-DTPA-enhanced-MRI and the feasibility of the application of half-dose Gd-EOB-DTPA to hepatobiliary phase imaging in patients with a BMI less than 24: a comparative study.Quant Imaging Med Surg. 2023 Sep 1;13(9):6176-6192. doi: 10.21037/qims-23-653. Epub 2023 Jul 21. Quant Imaging Med Surg. 2023. PMID: 37711824 Free PMC article.
-
Intratumoral and peritumoral radiomics model based on abdominal ultrasound for predicting Ki-67 expression in patients with hepatocellular cancer.Front Oncol. 2023 Aug 24;13:1209111. doi: 10.3389/fonc.2023.1209111. eCollection 2023. Front Oncol. 2023. PMID: 37711208 Free PMC article.
-
A precision image-guided model of stereotactic ablative radiotherapy for hepatocellular carcinoma.Dis Model Mech. 2025 May 1;18(5):dmm052301. doi: 10.1242/dmm.052301. Epub 2025 May 19. Dis Model Mech. 2025. PMID: 40241674 Free PMC article.
-
Analysis of risk factors of hepatocellular carcinoma and establishment of a clinical prognosis model.Front Oncol. 2023 Mar 22;13:1067353. doi: 10.3389/fonc.2023.1067353. eCollection 2023. Front Oncol. 2023. PMID: 37035138 Free PMC article.
References
-
- Ferlay J, Colombet M, Soerjomataram I, Parkin DM, Piñeros M, Znaor A, et al. . Cancer Statistics for the Year 2020: An Overview. Int J Cancer (2021). - PubMed
Publication types
LinkOut - more resources
Full Text Sources